Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer
Glutamate carboxypeptidase II (GCPII) is a membrane-bound binuclear zinc
metallopeptidase with the highest expression levels found in the nervous and prostatic …
metallopeptidase with the highest expression levels found in the nervous and prostatic …
Circulating tumor cells in prostate cancer: a potential surrogate marker of survival
J Doyen, C Alix-Panabieres, P Hofman… - Critical reviews in …, 2012 - Elsevier
Prostate-specific antigen (PSA) levels in blood are widely used in prostate cancer (PCa) for
the management of this disease at every stage of progression. Currently, PSA levels …
the management of this disease at every stage of progression. Currently, PSA levels …
Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy
SR Denmeade, AM Mhaka, DM Rosen… - Science translational …, 2012 - science.org
Heterogeneous expression of drug target proteins within tumor sites is a major mechanism
of resistance to anticancer therapies. We describe a strategy to selectively inhibit, within …
of resistance to anticancer therapies. We describe a strategy to selectively inhibit, within …
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate …
S Koochekpour, S Majumdar, G Azabdaftari… - Clinical cancer …, 2012 - AACR
Purpose: During glutaminolysis, glutamine is catabolized to glutamate and incorporated into
citric acid cycle and lipogenesis. Serum glutamate levels were measured in patients with …
citric acid cycle and lipogenesis. Serum glutamate levels were measured in patients with …
Glutamate carboxypeptidase II: an overview of structural studies and their importance for structure-based drug design and deciphering the reaction mechanism of the …
J Pavlicek, J Ptacek, C Barinka - Current medicinal chemistry, 2012 - ingentaconnect.com
Recent years witnessed rapid expansion of our knowledge about structural features of
human glutamate carboxypeptidase II (GCPII). There are over thirty X-ray structures of …
human glutamate carboxypeptidase II (GCPII). There are over thirty X-ray structures of …
A phosphoramidate‐based prostate‐specific membrane antigen‐targeted SPECT agent
JR Nedrow‐Byers, M Jabbes, C Jewett… - The …, 2012 - Wiley Online Library
BACKGROUND Prostate‐specific membrane antigen (PSMA) remains an active target for
imaging and therapeutic applications for prostate cancer. METHODS In the present study, an …
imaging and therapeutic applications for prostate cancer. METHODS In the present study, an …
Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization
CL Grant, LA Caromile, K Durrani, MM Rahman… - PLoS …, 2012 - journals.plos.org
Background Aberrant growth of blood vessels in the eye forms the basis of many
incapacitating diseases and currently the majority of patients respond to anti-angiogenic …
incapacitating diseases and currently the majority of patients respond to anti-angiogenic …
Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors
DV Ferraris, K Shukla… - Current medicinal …, 2012 - ingentaconnect.com
Glutamate carboxypeptidase II (GCPII, EC 3.4. 17.21) is a zinc metallopeptidase that
hydrolyzes N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate …
hydrolyzes N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate …
Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate
T Liu, JR Nedrow-Byers, MR Hopkins, LY Wu… - Bioorganic & medicinal …, 2012 - Elsevier
Prostate-specific membrane antigen (PSMA), a type II membrane glycoprotein, its high
expression is associated with prostate cancer progression, and has been becoming an …
expression is associated with prostate cancer progression, and has been becoming an …
Compositions and methods for the treatment of cancer
SR Denmeade, S Aggarwal - US Patent 8,258,256, 2012 - Google Patents
US8258256B2 - Compositions and methods for the treatment of cancer - Google Patents
US8258256B2 - Compositions and methods for the treatment of cancer - Google Patents …
US8258256B2 - Compositions and methods for the treatment of cancer - Google Patents …